U.S. Markets closed

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
46.40+1.10 (+2.43%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.30
Open45.10
Bid43.00 x 800
Ask46.28 x 800
Day's Range44.55 - 46.49
52 Week Range39.77 - 98.39
Volume1,223,812
Avg. Volume712,214
Market Cap2.713B
Beta (5Y Monthly)2.02
PE Ratio (TTM)3.98
EPS (TTM)11.66
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est85.11
  • Benzinga

    The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC) aTyr Pharma, Inc. (NASDAQ: LIFE) (reacted to positive analyst action following a positive clinical readout announced Monday) Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) BELLUS Health Inc. (NASDAQ: BLU) Itamar Medical Ltd. (NASDAQ: ITMR) IVERIC bio, Inc. (NASDAQ: ISEE) Kezar Life Sciences, Inc. (NASDAQ: KZR) PPD, Inc. (NASDAQ: P

  • Business Wire

    Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease

    CAMBRIDGE, Mass., September 15, 2021--Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SAGE-718 for development as a potential treatment for Huntington’s disease (HD). Fast Track is a process designed to facilitate the development and review of

  • Business Wire

    Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., September 02, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 10 at 12:30pm ET.